• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

缩短表位以存活:以 SARS-CoV-2 Lambda 变体为例。

Shortening Epitopes to Survive: The Case of SARS-CoV-2 Lambda Variant.

机构信息

Department of Biochemical Sciences "A. Rossi Fanelli", Sapienza Università di Roma, 00185 Rome, Italy.

Medical Statistic and Molecular Epidemiology Unit, University of Biomedical Campus, 00128 Rome, Italy.

出版信息

Biomolecules. 2021 Oct 10;11(10):1494. doi: 10.3390/biom11101494.

DOI:10.3390/biom11101494
PMID:34680128
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8533401/
Abstract

Among the more recently identified SARS-CoV-2 Variants of Interest (VOI) is the Lambda variant, which emerged in Peru and has rapidly spread to South American regions and the US. This variant remains poorly investigated, particularly regarding the effects of mutations on the thermodynamic parameters affecting the stability of the Spike protein and its Receptor Binding Domain. We report here an in silico study on the potential impact of the Spike protein mutations on the immuno-escape ability of the Lambda variant. Bioinformatics analysis suggests that a combination of shortening the immunogenic epitope loops and the generation of potential N-glycosylation sites may be a viable adaptation strategy, potentially allowing this emerging viral variant to escape from host immunity.

摘要

在最近被确定的 SARS-CoV-2 变体中,Lambda 变体引人注目,它最初在秘鲁出现,并迅速传播到南美地区和美国。目前对这种变体的研究还很不完善,特别是关于突变对影响 Spike 蛋白及其受体结合域稳定性的热力学参数的影响。在这里,我们报告了一项关于 Spike 蛋白突变对 Lambda 变体免疫逃逸能力潜在影响的计算研究。生物信息学分析表明,缩短免疫原性表位环和产生潜在 N-糖基化位点的组合可能是一种可行的适应策略,这可能使这种新出现的病毒变体能够逃避宿主免疫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3532/8533401/ce9f52c7636e/biomolecules-11-01494-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3532/8533401/3a3acda8bcf2/biomolecules-11-01494-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3532/8533401/9b0198d020d5/biomolecules-11-01494-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3532/8533401/ce9f52c7636e/biomolecules-11-01494-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3532/8533401/3a3acda8bcf2/biomolecules-11-01494-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3532/8533401/9b0198d020d5/biomolecules-11-01494-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3532/8533401/ce9f52c7636e/biomolecules-11-01494-g003.jpg

相似文献

1
Shortening Epitopes to Survive: The Case of SARS-CoV-2 Lambda Variant.缩短表位以存活:以 SARS-CoV-2 Lambda 变体为例。
Biomolecules. 2021 Oct 10;11(10):1494. doi: 10.3390/biom11101494.
2
Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.全面描述了针对 SARS-CoV-2 刺突蛋白的抗体反应,发现了除轻度感染诱导的表位之外的其他疫苗诱导的表位。
Elife. 2022 Jan 24;11:e73490. doi: 10.7554/eLife.73490.
3
Analysis Predicts a Limited Impact of SARS-CoV-2 Variants on CD8 T Cell Recognition.分析预测 SARS-CoV-2 变异对 CD8 T 细胞识别的影响有限。
Front Immunol. 2022 Apr 27;13:891524. doi: 10.3389/fimmu.2022.891524. eCollection 2022.
4
The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance.SARS-CoV-2 Lambda 变体表现出增强的感染力和免疫抗性。
Cell Rep. 2022 Jan 11;38(2):110218. doi: 10.1016/j.celrep.2021.110218. Epub 2021 Dec 18.
5
SARS-CoV-2 neutralizing antibody epitopes are overlapping and highly mutated which raises the chances of escape variants and requires development of broadly reactive vaccines.SARS-CoV-2 中和抗体表位重叠且高度突变,这增加了逃逸变异的可能性,需要开发广泛反应性的疫苗。
Proteins. 2023 Aug;91(8):1021-1031. doi: 10.1002/prot.26488. Epub 2023 Mar 21.
6
CD8 T-Cell Epitope Variations Suggest a Potential Antigen HLA-A2 Binding Deficiency for Spike Protein of SARS-CoV-2.CD8 T 细胞表位变异提示 SARS-CoV-2 刺突蛋白潜在的抗原 HLA-A2 结合缺陷。
Front Immunol. 2022 Jan 18;12:764949. doi: 10.3389/fimmu.2021.764949. eCollection 2021.
7
Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白受体结合域突变的计算分析及其对抗体结合的影响
Viruses. 2022 Jan 30;14(2):295. doi: 10.3390/v14020295.
8
Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.糖基化掩盖棘突蛋白 NTD 和 RBD 表位可诱导针对 SARS-CoV-2 变体的广泛中和抗体。
Front Immunol. 2021 Dec 2;12:795741. doi: 10.3389/fimmu.2021.795741. eCollection 2021.
9
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.MW06 是一种人源单克隆抗体,对 SARS-CoV-2 和 SARS-CoV 均具有交叉中和活性。
MAbs. 2021 Jan-Dec;13(1):1953683. doi: 10.1080/19420862.2021.1953683.
10
Peptidome Surveillance Across Evolving SARS-CoV-2 Lineages Reveals HLA Binding Conservation in Nucleocapsid Among Variants With Most Potential for T-Cell Epitope Loss in Spike.在 SARS-CoV-2 不断进化的谱系中进行肽组监测,揭示了核衣壳蛋白中与棘突蛋白中最有可能导致 T 细胞表位丢失的变异体具有 HLA 结合保守性。
Front Immunol. 2022 Jun 23;13:918928. doi: 10.3389/fimmu.2022.918928. eCollection 2022.

引用本文的文献

1
Two sides of the same coin: the N-terminal and the receptor binding domains of SARS-CoV-2 Spike.同一枚硬币的两面:新冠病毒刺突蛋白的N端结构域和受体结合结构域
Future Virol. 2023 Feb. doi: 10.2217/fvl-2022-0181. Epub 2023 Mar 6.
2
In Silico Analysis of the Effects of Omicron Spike Amino Acid Changes on the Interactions with Human Proteins.奥密克戎刺突氨基酸变化对与人蛋白相互作用影响的计算机分析。
Molecules. 2022 Jul 28;27(15):4827. doi: 10.3390/molecules27154827.
3
The SARS-CoV-2 Mu variant should not be left aside: It warrants attention for its immuno-escaping ability.

本文引用的文献

1
The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance.SARS-CoV-2 Lambda 变体表现出增强的感染力和免疫抗性。
Cell Rep. 2022 Jan 11;38(2):110218. doi: 10.1016/j.celrep.2021.110218. Epub 2021 Dec 18.
2
Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City.在纽约市的 SARS-CoV-2 疫苗突破性感染中,阿尔法和iota 变体占主导地位。
J Clin Invest. 2021 Sep 15;131(18). doi: 10.1172/JCI152702.
3
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
SARS-CoV-2 缪变异株不应被忽视:其免疫逃逸能力值得关注。
J Med Virol. 2022 Jun;94(6):2479-2486. doi: 10.1002/jmv.27663. Epub 2022 Feb 28.
最大限度提高广度和耐药逃逸能力的 SARS-CoV-2 RBD 抗体。
Nature. 2021 Sep;597(7874):97-102. doi: 10.1038/s41586-021-03807-6. Epub 2021 Jul 14.
4
SARS-CoV-2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?SARS-CoV-2 B.1.617 印度变异株:静电势变化是否与其更高的传播率有关?
J Med Virol. 2021 Dec;93(12):6551-6556. doi: 10.1002/jmv.27210. Epub 2021 Jul 27.
5
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.BNT162b2 诱导的针对 B.1.617 和其他 SARS-CoV-2 变体的中和作用。
Nature. 2021 Aug;596(7871):273-275. doi: 10.1038/s41586-021-03693-y. Epub 2021 Jun 10.
6
Integrated Biophysical Modeling of the SARS-CoV-2 Spike Protein Binding and Allosteric Interactions with Antibodies.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白与抗体结合及变构相互作用的综合生物物理建模
J Phys Chem B. 2021 May 13;125(18):4596-4619. doi: 10.1021/acs.jpcb.1c00395. Epub 2021 Apr 30.
7
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.SARS-CoV-2 变体 B.1.351 和 P.1 逃避中和抗体。
Cell. 2021 Apr 29;184(9):2384-2393.e12. doi: 10.1016/j.cell.2021.03.036. Epub 2021 Mar 20.
8
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.N 端结构域抗原性分析揭示了 SARS-CoV-2 的一个弱点。
Cell. 2021 Apr 29;184(9):2332-2347.e16. doi: 10.1016/j.cell.2021.03.028. Epub 2021 Mar 16.
9
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.SARS-CoV-2 B.1.1.7 对 mRNA 疫苗诱导抗体的敏感性。
Nature. 2021 May;593(7857):136-141. doi: 10.1038/s41586-021-03412-7. Epub 2021 Mar 11.
10
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.